Furthermore, we confirmed the relationship between IKAROS and CD19 surface expression in LBCL (Supplementary Fig. 4A–C) and CLL (Supplementary Fig. 4D) models, suggesting that IKAROS modulation of CD19 surface expression is consistent across B cell malignancies. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.